Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tyrosine kinase receptors, specifically ERBB receptors like EGFR, play a critical role in breast cancer growth and metastasis.
• Overexpression of HER2 and HER4 is significantly associated with human breast cancer development.
• Small molecule inhibitors targeting receptor tyrosine kinases (RTKs) offer a therapeutic strategy against cancer.

Purpose of the Study:

• To comparatively evaluate the inhibitory potential of structurally similar tyrosine kinase inhibitors (TKIs) against HER2 and HER4 receptors.
• To investigate the molecular interactions and binding patterns of these TKIs with HER2 and HER4 using in-silico methods.

Main Methods:

• Utilized in-silico molecular docking with FlexX software to assess TKI binding to HER2 and HER4.
• Analyzed docked complex interaction profiles using BIOVIA Discovery Studio Visualizer.
• Compared binding scores of various small molecule TKIs, including Lapatinib, Tivozanib, Erlotinib, Gefitinib, Crizotinib, and Ceritinib.

Main Results:

• Lapatinib demonstrated the highest binding scores (-32.36 kcal/mol with HER2 and -35.76 kcal/mol with HER4) among the tested compounds.
• Molecular docking analysis provided insights into the binding patterns and interactions of Lapatinib with both HER2 and HER4.
• Lapatinib was identified as a potent inhibitor for both HER2 and HER4 receptor tyrosine kinases.

Conclusions:

• Lapatinib is a promising candidate for inhibiting both HER2 and HER4, suggesting its potential in treating breast cancers driven by these RTKs.
• The findings support further investigation into Lapatinib's efficacy for inhibiting EGFR-family proteins in breast cancer.
• This study provides a computational basis for developing targeted therapies against HER2 and HER4 in breast cancer.